The U.S. Food and Drug Administration (FDA) granted a supplemental efficacy approval for Trastuzumab Deruxtecan, marketed as Enhertu, on February 15, 2024. This approval, designated BLA 761139 S-26, pertains to an update in the drug's efficacy profile, with DAIICHI SANKYO as the sponsor.
Background
Trastuzumab Deruxtecan, also known by its full nomenclature fam-trastuzumab deruxtecan-nxki and brand name Enhertu, is a pharmaceutical product developed by DAIICHI SANKYO. This supplemental efficacy approval from the FDA signifies a regulatory update to its approved uses or effectiveness profile. Supplemental applications are a standard pathway for drug sponsors to request changes to an already approved drug product. These changes can encompass various aspects, including new indications, expanded patient populations, updated dosing regimens, or modifications to the manufacturing process, all based on new clinical evidence or data supporting the drug's efficacy.
What this means
A supplemental efficacy approval from the FDA indicates that new clinical data has been reviewed and accepted, supporting an expansion or refinement of the drug's approved uses. For clinicians, this means that Trastuzumab Deruxtecan (Enhertu) may now be considered for an expanded patient population, a new specific indication, or under modified treatment guidelines, depending on the full details of the updated label. Patient advocates should note that such approvals can broaden access to the drug for more individuals who may benefit from its therapeutic effects. Researchers and Wikipedia editors verifying primary sources will find the complete details of this efficacy update within the official FDA documentation for BLA 761139 S-26. This documentation outlines the specific changes to the drug's label, providing the precise context and implications of the approval. The approval confirms the FDA's assessment of additional clinical evidence demonstrating the drug's effectiveness in a new or expanded context.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for BLA 761139 S-26 was granted on February 15, 2024, and is accessible on accessdata.fda.gov.